A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Trial · NCT02359058
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 58
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Ramucirumab + Capecitabine + Cisplatin | 1 | Participants | ||
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Ramucirumab + S-1 + Cisplatin | 2 | Participants | ||
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Ramucirumab + S-1 + Oxaliplatin | 2 | Participants | ||
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + Capecitabine + Cisplatin | Day 1 | 149 | Geometric Coefficient of Variation 21 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Cisplatin | Day 1 | 139 | Geometric Coefficient of Variation 23 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Oxaliplatin | Day 1 | 137 | Geometric Coefficient of Variation 20 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + Capecitabine + Cisplatin | Day 8 | 229 | Geometric Coefficient of Variation 24 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Cisplatin | Day 8 | 200 | Geometric Coefficient of Variation 21 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Oxaliplatin | Day 8 | 211 | Geometric Coefficient of Variation 11 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + Capecitabine + Cisplatin | Day 43 | 205 | Geometric Coefficient of Variation 24 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Cisplatin | Day 43 | 253 | Geometric Coefficient of Variation 11 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Oxaliplatin | Day 43 | 180 | Geometric Coefficient of Variation 28 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + Capecitabine + Cisplatin | Day 50 | 273 | Geometric Coefficient of Variation 24 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Cisplatin | Day 50 | 249 | Geometric Coefficient of Variation 24 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Oxaliplatin | Day 50 | 207 | Geometric Coefficient of Variation 12 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + Capecitabine + Cisplatin | Day 85 | NA | Geometric Coefficient of Variation NA | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Cisplatin | Day 85 | 272 | Geometric Coefficient of Variation 29 | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Oxaliplatin | Day 85 | NA | Geometric Coefficient of Variation NA | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + Capecitabine + Cisplatin | Day 92 | NA | Geometric Coefficient of Variation NA | microgram per milliliter (μg/mL) |
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab | Ramucirumab + S-1 + Cisplatin | Day 92 | 289 | Geometric Coefficient of Variation 22 | microgram per milliliter (μg/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02359058/results